Law360, New York (October 01, 2009, 4:07 PM ET) -- A judge has ruled that a Roche Palo Alto LLC patent used for the formulation of its anti-viral drug Valcyte is valid but that Ranbaxy Laboratories Ltd.’s generic version of the drug does not infringe it.
In a detailed 92-page order Judge Freda Wolfson of the U.S. District Court for the District of New Jersey said that Ranbaxy had failed to prove that the patent in question was invalid and that Roche could not prove Ranbaxy’s generic formulation of Valcyte contained a crystalline form of its...
Roche Valcyte Patent Ruled Valid, But Not Infringed
To view the full article, take a free trial now.
